Royalty Pharma plc Class A Ordinary Shares (RPRX) Valuation
Historical valuation analysis based on 500 data points (2024-09-27 to 2026-09-25)
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma r...
Royalty Pharma plc Class A Ordinary Shares (RPRX) currently trades at a P/E ratio of 39.18 (historical range: 12.63–43.05, median: 25.02), placing it at the 92th percentile — expensive relative to its history, P/S ratio of 13.28 (range: 6.38–14.59, 92th percentile — expensive relative to its history), EV/EBITDA of 25.42 (range: 12.29–27.44, 92th percentile).
Over the historical period (2024-09-27 to 2026-09-25), Royalty Pharma plc Class A Ordinary Shares's P/E ratio has expanded by 98% over the observed period (from an average of 17.0 to 33.7).
Royalty Pharma plc Class A Ordinary Shares trades well above its own historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 39.18 | 12.63 | 25.02 | 43.05 | 92th | expensive relative to its history |
| P/S Ratio | 13.28 | 6.38 | 9.02 | 14.59 | 92th | expensive relative to its history |
| EV/EBITDA | 25.42 | 12.29 | 18.01 | 27.44 | 92th | expensive relative to its history |
Royalty Pharma plc Class A Ordinary Shares (RPRX) Valuation & P/E History
Royalty Pharma plc Class A Ordinary Shares (RPRX) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry currently trading at $58.27 with a market capitalization of $25.9 billion. This page provides historical valuation analysis for RPRX based on 500 data points covering 2024-09-27 to 2026-09-25. The P/E ratio of 39.18 is above the historical median of 25.02, placing RPRX at the 92th percentile of its valuation range. The P/S ratio of 13.28 compares to a median of 9.02.
RPRX Valuation Metrics & Historical Range
The valuation table above shows Royalty Pharma plc Class A Ordinary Shares's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether RPRX is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests RPRX is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Royalty Pharma plc Class A Ordinary Shares.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is RPRX Overvalued or Undervalued?
Royalty Pharma plc Class A Ordinary Shares trades well above its own historical valuation range across most metrics. The overall valuation percentile of 92 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive RPRX is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full RPRX analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.RPRX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.